Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gene Therapy Libmeldy Undergoes Cross-Country HTA In Europe

Executive Summary

Cross-country drug access coalition BeNeLuxA is reviewing the costly one-off gene therapy for children with metachromatic leukodystrophy.

You may also be interested in...



Europe: Cross-Country HTA of Gene Therapy Libmeldy Calls For Price Cut

Joint price negotiations for Orchard’s gene therapy Libmeldy could follow outcome of multi-country health technology assessment.

Orchard Secures New Libmeldy Price In Germany

Orchard Therapeutics says it is confident in the success of its gene therapy for MLD, which has secured the highest possible benefit rating from the German authorities.

European Countries Focus Horizon Scanning On Alzheimer’s Disease

Working out what’s on the horizon in terms of potential new treatments for Alzheimer’s disease should help countries prepare for the challenges that will be involved when it comes to determining patient access.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS145794

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel